Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1811 (LINC01811)
- Target
- LINC01811
- Molecular classification
- Long non-coding RNA (lncRNA), Other (Non-protein coding regulatory RNA)
01
Overview
Long intergenic non-protein coding RNA 1811 (LINC01811) is a lncRNA highly expressed in colorectal cancer tissues and cell lines compared to normal tissue. It functions as an oncogenic factor primarily by sponging miR-214-3p, thereby increasing *YAP1* expression and promoting cell migration, invasion, and epithelial-mesenchymal transition. LINC01811 silencing reduces metastatic potential and alters mRNA/protein levels of EMT-related markers (such as vimentin, MMP2, MMP9, and E-cadherin). Its role as a ceRNA highlights its potential as a biomarker and a novel therapeutic target in colorectal cancer. There are currently no drugs directly targeting LINC01811, but its regulatory axis (LINC01811/miR-214-3p/YAP1) presents a promising area for future drug development.
- Other names
- LINC01811Long intergenic non-protein coding RNA 1811
02
Mechanism of action
LINC01811 acts by sponging microRNA (miR-214-3p), which leads to increased expression of *YAP1*, a known oncogenic factor in CRC progression. Targeting LINC01811 may inhibit invasion and migration of cancer cells by reversing EMT and reducing matrix metalloproteinase activity (MMP2, MMP9).
03
Biological functions
Competing endogenous RNA (“ceRNA” sponge for miR-214-3p)Regulator of epithelial-mesenchymal transition (EMT)Promotes cell migration and invasion in colorectal cancerUpregulates YAP1 expression indirectly via miR-214-3p sequestration
04
Disease associations
Cancer (colorectal cancer, with emerging evidence in ovarian cancer)Potential in other malignancies based on lncRNA regulatory pathways
05
Safety considerations
As with most lncRNAs, therapeutic modulation presents delivery and specificity challengesOff-target effects have not been deeply characterized, but targeting a lncRNA could affect multiple pathways due to ceRNA networks
06
Biomarkers
Elevated LINC01811 expression in CRC tissues may serve as a diagnostic/prognostic biomarkerExpression of miR-214-3p and YAP1 as downstream effectors and surrogate markersEMT markers (Vimentin downregulated and E-cadherin upregulated when LINC01811 is silenced)
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 1811 (LINC01811).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1811 (LINC01811).